Pre-Register

Introducing the Thermo Scientific™ Cascadion™ SM Clinical Analyzer: Accuracy. Ease-of-Use. Designed for the Clinical Lab
Sarah Robinson, PhD, Market Development Specialist, Thermo Fisher Scientific

The Cascadion SM Clinical Analyzer is the first all-in-one LC-MS/MS solution designed to meet the needs of clinical laboratories. Our fresh vision for fully automated liquid chromatography-tandem mass spectrometry (LC-MS/MS) testing was cultivated by listening to our customers. You asked for a complete solution that was accurate, easy-to-use, and designed for the clinical laboratory. The Cascadion Clinical Analyzer is designed as a turnkey solution to enable clinical labs to easily adopt the power and capabilities of LC-MS/MS as the gold standard in diagnostic testing. The Cascadion system combines assays, software, accessories, consumables and support/service in a standalone system designed to meet the regulatory requirements for routine and specialized clinical testing. This presentation will showcase the Cascadion solution.
This product is in development and not yet available for sale. This product is not CE marked or FDA 510(k) cleared.

Pre-Register

SWATH®-MS for Quantitation and Identification in Clinical Proteomics, Lipidomics, and Metabolomics

SWATH®-MS, a data-independent MSMS analysis (DIA) was originally developed for proteomics, to quantify thousands of tryptic peptides during one LC run without selection of a given precursor ion. Using a database containing the experimentally measured MSMS spectra, quantitative analysis of proteins has been achievable for several years. Recent software developments have permitted protein quantification to be performed in tandem with protein identification.
In lipidomics, also a complex class of compounds, the MSMS behavior of certain lipid groups is often characterized by isobaric precursors and daughter ions, but different structures. This precludes using normal SWATH®-LC applications, but by introducing ion mobility analysis with a DIA approach, isobaric lipids can be separated and quantified. By coupling direct infusion on a TripleTOF® 6600 system with high field ion mobility (using a SelexION® DMS cell), DIA is performed in 1 Da windows (MSMSALL).
The pros and cons will be shown for all the three fields of clinical proteomics, lipidomics, and metabolomics where the high numbers of samples require a robust method resulting in the use of micro-LC.

Pre-Register

Disruptive Technologies and Creative Solutions in Clinical Mass Spectrometry

1. Application of the fully-automated sample preparation module, CLAM-2000, in clinical diagnostics
Dr. Thomas Stimpfl, Medical University of Vienna - Department of Laboratory Medicine
In clinical diagnostics random access to wide range of target analytes is needed. We will present experience with a novel, fully-automated sample preparation module - directly connected to a LC-MS-system - in the routine setting of a university hospital laboratory.

2. Rethinking library identification in quantitative clinical toxicology - transitioning towards MRM spectrum mode
Neil Loftus - SHIMADZU Corporation (UK)
Translating information-rich mass spec data into meaningful test results is a hurdle in many labs. To help transition toward high-confidence result reporting we have been rethinking the use of MRM in compound identification. We will show how MRM can help reduce false-positive and false-negative reporting without affecting quantitative data quality.

For Research Use Only. Not diagnostic use. Not available in USA or Canada. This presentation may contain references to products not available in your country. All rights reserved. Information subject to change without notice.

Pre-Register

Introducing the New SCIEX Topaz™ System, a CE-marked Integrated LC-MS-based IVD System

SCIEX is proud to launch the new TOPAZ System for Clinical Diagnostics at MSACL EU 2017. In this seminar, we will present the system and its capabilities, in particular the new ClearCore MD software designed specifically for clinical diagnostics. We will show how the system, based on strong and established mass spectrometry technology, brings enhanced ease-of-use to the diagnostic laboratory, exploiting the power of mass spectrometry to address the diagnostic challenges of today and tomorrow. Seminar delegates will have the opportunity to see and discuss real-world examples of the multitude of diagnostic applications the TOPAZ system is capable of, and meet European leaders in the diagnostics arena as well as SCIEX Diagnostics global experts in the field.

Pre-Register

Protein Quantification in the clinical laboratory. Challenges and opportunities for improved assays with LC/MS.

Although LC/MS has been successfully used and widely adopted for many small molecule clinical assays, the technique has yet to make a big impact for peptide and protein quantitation applications in the clinical laboratory. With increasingly sensitive instruments and robust micro fluidic inlet devices combined with efficient and standardised sample pre-treatment protocols LC/MS may now be ready for routine protein applications. Challenges and opportunities for LC/MS in protein and peptide biomarker assays and therapeutic drug monitoring of monoclonal antibody (mAb) drugs will be presented.

Pre-Register

This workshop examines how two experts used Volumetric Absorptive Microsampling (VAMS™) technology to generate results comparable to those from wet blood, using a variety of analytes and eliminating the hematocrit bias associated with traditional Dried Blood Spot (DBS) cards and filter paper.

Volumetric Absorptive Microsampling (VAMS) and LC-MS/MS Analysis for Simultaneous Monitoring of 16 Antiepileptic Drugs: Workflow Development and Validation
Dr. Ugo de Grazia, Nazionale Neurologico Carlo Besta, Italy

Steroid Collection Using the Mitra Microsampling Device
Prof. Brian Keevil, University Hospital of South Manchester, United Kingdom

Pre-Register

Quantitation of endocrine markers using High Resolution Mass Spectrometry
Laura Owen – University Hospital of South Manchester
Traditionally the quantitation of endocrine biomarkers has been performed using triple quadrupole analysers whereas orbitrap technology lends itself primarily to drug monitoring and screening applications. However, in recent years, orbitrap high resolution mass spectrometry systems have proved to be a great screening and quantitation tools.
Our research goal was to quantify renin activity, aldosterone and metanephrines using orbitrap HRMS, in order to bring an added level of capability and flexibility to our lab. For plasma renin analysis, data was acquired in both PRM and full scan modes while, for aldosterone analysis, extract was analysed by PRM only with negative ion mode. Renin activity was measured at concentration level typically found in Conn’s syndrome with sufficient sensitivity. PRM showed slightly superior sensitivity than full scan mode. Metanephrine and normetanephrine both gave adequate sensitivity and calibration lines however 3-methoxytyramine was not sufficiently sensitive. Aldosterone demonstrated good sensitivity in sub 100pmol/L concentrations.
The QE focus demonstrated its ability to quantify difficult to measure endocrine markers offering quantitation capabilities along with full scan thus bringing screening, protein discovery and quantitative capabilities to the clinical laboratory.

Pre-Register

Automation in Clinical Labs

1. Automation and Integration of LC/MS/MS Assays into the Workflow of a Clinical Laboratory
Emma Walker (Imperial College Healthcare NHS Trust)
Automation of sample preparation and interfacing of the LC-MS/MS system to the laboratory information system has the potential to reduce staff time and increase sample throughput. In her talk, Emma will present the approaches she has taken to streamline sample extraction utilizing Tecan Freedom Evo platforms within her laboratory. For example the endocrinology service is using the automated SPE 96-well plates format to screen patients for testosterone, androstenedione and 17-hydroxyprogesterone. The steroid panel assay runs two or three times a week, and it takes approximately 90 minutes to prepare for analysis - short overview about workflow, turnaround times, efficiency and standardization.

2. Drug Screening in Whole Blood Using Fully Automated SPE and UHPLC-TOF-MS
Brian Schou Rasmussen (University of Copenhagen, Forensic Chemistry)
Brian will present experiences from the automation of sample preparation in a forensic toxicology LC-MS analysis on a robotic platform. Workflow strategies, sample throughput, cost efficiencies and special considerations concerning forensic samples with be discussed.

Pre-Register

Multiplexed Proteomic Analysis – The Need for Speed without Compromises
Dr. Cory Bystrom, VP of Research and Development Clevland Heart Laboratory

High density lipoprotein (HDL) plays a number of roles in vascular biology, including lipid and cholesterol transport, anti-oxidative and anti-thrombotic activity, endothelial regulation, and immune response regulation. Cholesterol efflux capacity (CEC), the transport of intracellular cholesterol from macrophages to an accepting HDL particle. The CEC assay is a challenging cell based assay that is labor intensive and low throughput. To enable research investigating CEC and its role in atherosclerotic plaque development we have developed a multiplex proteomic approach to estimating cholesterol efflux from a measurement of six lipoproteins.

Targeted Metabolomics in Personalized Cancer Medicine

Dr. David Wishart: “Metabolomics for Precision Cancer Prevention and Screening”
Dr. Werner Scheuer: “Utility of Metabolomics to Monitor Drug Efficacy in Cancer Models”

Although metabolites have been used in clinical diagnostics for decades, currently clinicians only use a fraction of the information contained in the metabolome. It is anticipated that the measurement of single metabolic substances will be replaced by more comprehensive metabolic signatures. Targeted metabolomics, the hypothesis driven analysis of selected metabolites, will be an important technology for the identification of such biomarker signatures.

Historically, cancer has been thought to be a metabolic disorder. While the focus had turned to genetic approaches, a growing body of evidence confirms an important role for metabolic factors in the pathogenesis and outcome of many different malignancies. This has led to renewed interest into cancer metabolism.

Targeted metabolomics has been instrumental for the identification of metabolic factors that modulate cancer risk, as well as blood based biomarkers for early diagnosis and prognosis. The technology has also provided predictive biomarker signatures for response to targeted and chemotherapies.


Products mentioned in the workshop may currently be labeled for research use only – not for use in diagnostic procedures.

Pre-Register

New advances and technologies in Mass Spectrometry for Clinical Research

Mass Spectrometry, particularly LC-MS, has had significant impact into clinical research over a number of years now. In particular, LC-MS has revolutionised small molecule analysis, addressing analytical challenges and pushing limits in fields such as biomarker discovery and analysis of challenging compounds such as Steroids and Dihydroxyvitamin D. We present here a discussion on the novel approaches to furthering the capabilities of such applications, in particular the use of complimentary techniques such as Ion Mobility and simple sample preparation chemistries. Seminar delegates will have the opportunity to see examples of the multitude of research applications empowered by such technology advances, and discuss their impact with SCIEX experts in the field.